Sustained response to lenalidomide for early relapsed marginal zone lymphoma

Blood Cells Mol Dis. 2018 Jul:71:53-54. doi: 10.1016/j.bcmd.2018.02.004. Epub 2018 Feb 23.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use*
  • Female
  • Humans
  • Lenalidomide / administration & dosage
  • Lenalidomide / adverse effects
  • Lenalidomide / therapeutic use*
  • Lymph Nodes / pathology
  • Lymphoma, B-Cell, Marginal Zone / diagnosis*
  • Lymphoma, B-Cell, Marginal Zone / drug therapy*
  • Middle Aged
  • Neck
  • Recurrence
  • Tomography, X-Ray Computed / methods
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Lenalidomide